Molecular targeting of pancreatic disorders.
During the last decade significant advances in gene therapy have made it possible to treat various pancreatic disorders in both animal models and in humans. For example, insulin gene delivery to non-beta-cell tissues has been shown to reverse hyperglycemia in diabetic mice, and islet transplantation, based on in vitro differentiation of beta cells and concomitant gene targeting to prevent host autoimmune responses, has become more feasible. Additionally, introduction of the glucokinase regulatory protein and protein kinase C-zeta have been shown to improve glucose tolerance in non-insulin-dependent diabetes mellitus animal models. Pancreatic cancer studies utilize several DNA-based strategies for tumor treatment including introduction of tumor suppressor genes, suppression of oncogenes, suicide gene/prodrug therapy, and restricted replication-competent virus therapy. Tumor-specific targeting is an important part of suicide gene therapy, and tumor-specific promoters are used for cell-specific targeting. Tumor-specific suicide gene therapy directed by the rat insulin promoter has been used to eliminate insulinoma tumors in a mouse model. This review compiles a compendium of information related to the treatment of pancreatic disorders using gene therapy.
Tamada
Kiichi
K
Michael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA.
Wang
Xiao-Ping
XP
Brunicardi
F Charles
FC
D000818:Animals; D002908:Chronic Disease; D003920:Diabetes Mellitus / Q000235:genetics* / Q000628:therapy; D018390:Gene Targeting; D015316:Genetic Therapy; D006801:Humans; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000628:therapy; D010195:Pancreatitis / Q000235:genetics* / Q000628:therapy